Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04501718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 15, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Aug 31, 2024 to Aug 31, 2025
    • Site contact updated
    v6
  2. 2 versions Re-verified since Feb 10, 2022, no change to tracked fieldsv4-v5
  3. Start date changed from estimate of Aug 2020 to Oct 28, 2020
    • Site contact updated
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective single-center clinical study, which aims to observe and evaluate the efficacy and safety of apatinib combined with temozolomide and oral etoposide in the treatment of recurrent medulloblastoma in children.
Trial Details
NCT Number NCT04501718
Lead Sponsor Beijing Sanbo Brain Hospital
Conditions
(from sponsor)		 Recurrent Medulloblastoma
Related terms Medulloblastoma
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov